Document is current
Any future updates will be listed below
-
Authors
Kheirkhah, Mina
Duncan, Wallace C. Jr
Yuan, Qiaoping
Wang, Philip R.
Jamalabadi, Hamidreza https://orcid.org/0000-0003-2485-2374
Leistritz, Lutz
Walter, Martin https://orcid.org/0000-0001-7857-4483
Goldman, David https://orcid.org/0000-0002-1724-5405
Zarate, Carlos A. Jr
Hejazi, Nadia S.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (ZIAMH002857)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (ZIAMH002857)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (ZIAMH002857)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (ZIAMH002857)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (ZIAMH002857)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (ZIAMH002857)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (ZIAMH002857)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (ZIAMH002857)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (ZIAMH002857)
Deutsche Forschungsgemeinschaft (499724048)
Deutsche Forschungsgemeinschaft (499724048)
Deutsche Forschungsgemeinschaft (499724048)
Deutsche Forschungsgemeinschaft (499724048)
Deutsche Forschungsgemeinschaft (499724048)
Deutsche Forschungsgemeinschaft (499724048)
Deutsche Forschungsgemeinschaft (499724048)
Deutsche Forschungsgemeinschaft (499724048)
Deutsche Forschungsgemeinschaft (499724048)
Deutsche Forschungsgemeinschaft (499724048)
- License Information
-
More Information
Article History
Received: 10 October 2024
Revised: 6 January 2025
Accepted: 6 February 2025
First Online: 15 February 2025
Competing interests
: Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2 R,6 R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2 R,6 R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.
